Dr. Mark E. Johns, MD
Hematology & Oncology (Hematology & Oncology Physician)
601 Ivy Gtwy Ste 1100
Cincinnati, OH 45245
Who else practices at this address →
Clermont County includes primary care (8% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 660
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Ohio State University College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35.125806 -
Medical Oncology Physician
MN license 47008
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bethesda North Cincinnati, OH
- The Jewish Hospital-Mercy Health Cincinnati, OH
- Mercy Health-Anderson Hospital Cincinnati, OH
- Mercy Health - Clermont Hospital Batavia, OH
Medical groups
- Oncology Hematology Care Inc (63 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 660
- Services billed
- 145,631
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 18,360 | 18 |
| Injection, oxaliplatin, 0.5 mg | 17,200 | 12 |
| Injection, pembrolizumab, 1 mg | 11,801 | 15 |
| Injection, fosaprepitant, 1 mg | 11,250 | 15 |
| Injection, paclitaxel, 1 mg | 4,968 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,816 | 83 |
| Injection, palonosetron hcl, 25 mcg | 2,230 | 50 |
| Injection, atropine sulfate, 0.01 mg | 1,880 | 13 |
| Injection, leucovorin calcium, per 50 mg | 1,695 | 22 |
| Injection, ferric derisomaltose, 10 mg | 1,100 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Cincinnati, OH | 613 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 165 |
| Alendronate Sodium Other prescribers in Cincinnati, OH | 149 |
| Oxycodone Hcl Other prescribers in Cincinnati, OH | 148 |
| Ondansetron Hcl Other prescribers in Cincinnati, OH | 135 |
| Prochlorperazine Maleate Other prescribers in Cincinnati, OH | 124 |
| Calquence (acalabrutinib maleate) | 107 |
| Dexamethasone Other prescribers in Cincinnati, OH | 87 |
| Prednisone Other prescribers in Cincinnati, OH | 86 |
| Hydroxyurea Other prescribers in Cincinnati, OH | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 19 payments worth $825 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $542 |
|---|---|
| Janssen Biotech, Inc. | $99.99 |
| AstraZeneca Pharmaceuticals LP | $83.59 |
| Pfizer Inc. | $56.93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.67 |
| Aveo Pharmaceuticals, Inc. | $20.37 |
| Long term medical supply or device loan | $482 |
|---|---|
| Food and Beverage | $200 |
| Education | $143 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 12, 2025 | Education ERLEADA · Oncology · in-kind | $99.99 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $174,528 in research payments for these studies, mostly to the institutions running them.
- BNT000-001
BioNTech SE - BNT-122-01
BioNTech SE - A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
AbbVie Inc. · Recruiting · NCT06820463 - BNT122
BioNTech SE - A Phase 2, Openlabel, Randomized Controlled Trial of BMS986218 or BMS986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castrationresistant Prostate Cancer
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC - An interventional phase 3 doubleblind randomized study to evaluate the efficacy and safety of PF08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatmentnaÏve participa…
Pfizer Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.